BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.18 (-1.69%)

Stability Price

Overvalued by 98.22%

Company Metrics

  • 0 P/E
  • 40.98 P/S
  • 9.20 P/B
  • -0.613 EPS
  • -118.77% Cash ROIC
  • 2.49 Cash Ratio
  • 0.00 / N/A % Dividend
  • 857,055.00 Avg. Vol.
  • 754.6M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Stock Insight: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Jan 29, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of ...
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
Seeking Alpha (registration) - Jan 27, 2015
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ... - Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - CNNMoney
BioCryst Pharmaceuticals, Inc. Short Interest Disclosure
Bar and Graph Report - 48 minutes ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) encountered a rise of 3.6% or 382,170 shares in the short positions. The number escalated from 10,575,643 on December 31,2014 to 10,957,813 on January 15,2015.
Company Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Jan 21, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for ...
BioCryst Pharmaceuticals Given Average Recommendation of "Buy" by ... - The Legacy
BioCryst Pharmaceuticals, Inc. Price Target Update - Bar and Graph Report
Brokerage Firm Price Target on BioCryst Pharmaceuticals, Inc.
Stafford Daily - Jan 22, 2015
Equity Analysts at the Brokerage Firm, JP Morgan, maintains their rating on the shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). JP Morgan has a Overweight rating on the counter. As per the latest research report, the brokerage house lowers the ...
Stock in Focus: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Jan 12, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at ...
BioCryst Pharmaceuticals Raised to "Outperform" at Zacks (NASDAQ:BCRX) - Mideast Time
Shares Outperform Index: Ship Finance International Ltd , BioCryst ... - Rock Hill Daily
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
TheStreet.com - Dec 26, 2014
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Traders Buzz: Arch Coal Inc. (NYSE:ACI), BioCryst Pharmaceuticals (NASDAQ ... - Property Mentor
Why BioCryst Pharmaceuticals Inc. Shares Soared
Motley Fool - May 27, 2014
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Crushes It on Rare Immune Disorder Drug Trial - 24/7 Wall St.
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ... - MarketWatch
CFO of BioCryst Pharmaceuticals, Inc. Sells Company Shares
Ashburn Daily - Jan 22, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Staab Thomas R Ii, Senior Vice President and CFO of Biocryst Pharmaceuticals Inc, unloaded 9,500 shares at an average price of $12.56 on December 29, 2014. The total amount of the transaction was worth ...
BioCryst Pharmaceuticals, Inc. Analyst Rating Update
Stafford Daily - Jan 13, 2015
Research firm Zacks has rated BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and has ranked it at 1, indicating that its shares are a Outperform.
Buzz Stocks: Tesla Motors, Inc., Chipotle Mexican Grill, Inc., and BioCryst ... - Schaeffers Research (blog)
Pre-market Bullish Movers: Himax Technologies (ADR) (NASDAQ:HIMX ... - Property Mentor